KalVista Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) was the target of some unusual options trading activity on Friday. Stock traders acquired 5,072 call options on the stock. This represents an increase of approximately 569% compared to the typical volume of 758 call options.

Analysts Set New Price Targets

KALV has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. HC Wainwright boosted their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Finally, Citizens Jmp decreased their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Thursday. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $32.60.

KalVista Pharmaceuticals News Roundup

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating, signaling significant upside versus the current share price. Stifel Price Target Raise
• Positive Sentiment: Needham & Company increased its price target to $36 and maintained a “buy” rating, adding to analyst momentum behind the stock. Needham Price Target Raise
• Positive Sentiment: Company reported a strong commercial start for EKTERLY, posting $49.1M in EKTERLY revenue during an eight‑month transition period — a tangible revenue data point supporting the bull case. EKTERLY Revenue Report
• Positive Sentiment: Unusually large options activity: traders bought 5,072 KALV call options (≈569% above normal call volume), indicating speculative or hedged bullish positioning by options market participants.
• Positive Sentiment: Stock hit a new 52‑week high following analyst upgrades, reinforcing momentum and attracting technical buyers. 52‑Week High / Analyst Upgrade
• Neutral Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 but kept a “market outperform” rating — a modest mixed signal compared with other, larger raises. Citizens Jmp Note
• Neutral Sentiment: Recent earnings/earnings‑call transcripts and summaries (Q4/8‑month and Q1 2025 materials) are available for deeper review; these provide context on commercial rollout, margins and guidance but contain no single surprise that would alone explain the move. Q1 2025 Call Summary 8‑Month Transcript

Insider Activity at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 5,354 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $83,361.78. Following the sale, the insider directly owned 138,983 shares of the company’s stock, valued at $2,163,965.31. This trade represents a 3.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Brian Piekos sold 1,767 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $27,512.19. Following the transaction, the chief financial officer owned 13,762 shares in the company, valued at $214,274.34. This represents a 11.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 33,378 shares of company stock worth $522,290 in the last three months. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Emerald Advisers LLC raised its holdings in shares of KalVista Pharmaceuticals by 30.2% in the third quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock valued at $16,458,000 after buying an additional 313,205 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $24,360,000. Jefferies Financial Group Inc. acquired a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $3,494,000. Blue Owl Capital Holdings LP bought a new position in shares of KalVista Pharmaceuticals in the third quarter worth about $1,522,000. Finally, Stonepine Capital Management LLC raised its stake in shares of KalVista Pharmaceuticals by 364.0% in the second quarter. Stonepine Capital Management LLC now owns 100,000 shares of the specialty pharmaceutical company’s stock worth $1,130,000 after acquiring an additional 78,450 shares during the last quarter.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV traded up $0.19 during mid-day trading on Friday, hitting $19.14. 856,055 shares of the stock were exchanged, compared to its average volume of 1,026,048. The company has a market cap of $967.32 million, a P/E ratio of -4.85 and a beta of -0.35. The stock’s fifty day simple moving average is $15.95 and its two-hundred day simple moving average is $14.44. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. KalVista Pharmaceuticals has a twelve month low of $9.23 and a twelve month high of $19.95.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.